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Abstract: The diagnosis of mantle cell lymphoma (MCL) can be
diﬃcult, especially when no t(11;14) translocation and cyclin D1
overexpression can be detected. In such cases, the transcription
factor SOX11 represents an important diagnostic marker, as it is
expressed in most MCLs and, in particular, in all cyclin D1-
negative MCLs reported so far. A reliable anti-SOX11 antibody
is therefore a very useful tool for routine diagnosis. Here, we
characterize the new monoclonal anti-SOX11 antibodies, suit-
able for Western blot assay and immunohistochemistry (IHC)
on formalin-ﬁxed paraﬃn-embedded tissue; we tested them on a
large series of primary lymphoid tumors and compared these
results with those of other routinely used antibodies. Moreover,
we show that IHC results depend on transcription levels of
SOX11, which suggests that posttranscriptional and post-
translational modiﬁcations do not signiﬁcantly aﬀect cutoﬀ
levels for IHC detection of SOX11.
Key Words: SOX11, mantle cell lymphoma, monoclonal anti-
body, qRT-PCR
(Am J Surg Pathol 2014;38:86–93)
Mantle cell lymphoma (MCL) is a B-cell neoplasm,which usually presents with advanced stage, rapid
clinical progression, and a median survival of 3 to 5
years.1 The distinction of MCL from other B-cell lym-
phomas, which might present with similar histologic
features, such as chronic lymphocytic leukemia/small
lymphocytic lymphoma, follicular lymphoma, and mar-
ginal zone lymphoma, is therefore of major importance.
In addition to clinical data and histomorphology, im-
munohistochemistry (IHC) and genetic analyses are re-
quired for a correct diagnosis. In particular, the detection
of a t(11;14) translocation, which leads to the over-
expression of cyclin D1, represents an indispensable di-
agnostic tool as it can be demonstrated in 90% of the
MCLs.1–3 Interestingly, MCLs lacking both a t(11;14)
translocation and cyclin D1 expression but with a gene
expression proﬁle similar to that of cyclin D1-positive
MCLs have been recognized.3 Additional studies led to
the discovery of SOX11, which is expressed in 78% to
100% of MCLs, including the cyclin D1-negative var-
iant,4–7 and appears to be the best discriminatory marker
for the identiﬁcation of a subgroup of MCL patients with
clinical indolent behavior.8,9 SOX11 represents, therefore,
an important diagnostic and prognostic marker.
The SOX11 gene, mapping at chromosome 2p25.3,
encodes a transcription factor of 441 amino acids, which
belongs to a family of approximately 20 genes characterized
by the presence of a conserved DNA-binding high-mobility
group domain. SOX genes are divided into 8 subgroups
according to the degree of homology of the high-mobility
group domain, and SOX11, together with SOX4 and
SOX12, belong to subgroup C.10 SOXC genes are ex-
pressed during embryogenesis in neuronal progenitors and
From the *Hematopathology Unit, Pathology Department, Hospital
Clı´nic; zInstitut d’Investigacions Biome`diques August Pi i Sunyer
(IDIBAPS); yDepartment of Anatomic Pathology, Pharmacology
and Microbiology, University of Barcelona, Barcelona, Spain; wIn-
stitute of Surgical Pathology, University Hospital Zurich, Zurich,
Switzerland; and 8Research and Development, Atlas Antibodies,
Stockholm, Sweden.
D.S. and A.V. contributed equally.
Conﬂicts of Interest and Source of Funding: D.S. is supported by the
Swiss National Science Foundation and by the Swiss Cancer League.
A.M. and C.S. are supported by Fondo de Investigacio´n Sanitaria,
PI11/00907; “Red Tema´tica de Investigacio´n Cooperativa de
Ca´ncer” (RTICC) RD12/0036/0004; and FEDER One way to
Europe. E.C. is supported by the CICYT SAF 08/SAF 2008-03630
and Instituto de Salud Carlos III, RD12/0036/0023.
Correspondence: Antonio Martinez, MD, PhD, Department of Ana-
tomic Pathology, Hospital Clinic, Villarroel 170, 080136-Barcelona,
Spain (e-mail: antonmar@clinic.ub.es).
Supplemental Digital Content is available for this article. Direct URL
citations appear in the printed text and are provided in the HTML
and PDF versions of this article on the journal’s Website, www.ajsp.
com.
Copyright r 2013 by Lippincott Williams & Wilkins
ORIGINAL ARTICLE
86 | www.ajsp.com Am J Surg Pathol  Volume 38, Number 1, January 2014
in mesenchymal cells of many organs. Moreover, SOX11
and SOX4 are expressed in medulloblastomas and malig-
nant gliomas.11,12 In hemato-lymphoid tissues, SOX4 is the
only member of the SOX family that has been shown to
play a role in the physiological B-cell and T-cell develop-
ment,13,14 whereas its expression in hemato-lymphoid neo-
plasms is restricted to adult T-cell leukemia/lymphoma.15
So far, most IHC studies aiming at characterizing the
expression of SOX11 on formalin-ﬁxed paraﬃn-embedded
(FFPE) tissues have been performed with polyclonal anti-
bodies.4–7,16 Despite their satisfactory diagnostic results in
MCL, polyclonal anti-SOX11 antibodies have some limi-
tations including certain unspeciﬁc reactions, such as cyto-
plasmic staining in normal tissues and in lymphomas lacking
SOX11 mRNA expression,4,5 as well as batch to batch var-
iation in their reactivity, which represent major limiting
factors. Recently, the monoclonal anti-SOX11 antibodies
have been presented; however, their capacity to discriminate
against SOX4 has not been tested.17 Moreover, no study has
compared IHC results with transcriptional activity for
SOX11, so far. The aim of this study was to investigate the
possible relationship existing between mRNA levels and IHC
detection for SOX11, to compare the properties of the most
commonly used anti-SOX11 antibodies on IHC and Western
blot, and to characterize the new mouse monoclonal anti-
bodies and to deﬁne its potential diagnostic value for MCL.
MATERIALS AND METHODS
Patient Samples
A large series of 209 primary lymphoid tumors di-
agnosed according to the last World Health Organization
2008 classiﬁcation1 was selected for the study. The diag-
noses of these cases are summarized in Table 1. Samples
were obtained from the tumor bank of the Department of
Pathology, Hospital Clinic, University of Barcelona. The
study was approved by the Ethic Committee of the
Hospital Clinic of Barcelona.
IHC and Fluorescence In Situ Hybridization
Analysis
Tissue microarray sections were prepared from
FFPE material derived from 153 of 209 cases selected for
the study; the 57 remaining cases were examined on
whole-tissue sections. Besides cyclin D1 (clone EP12;
Thermo Fisher Scientiﬁc, Runcorn, UK), all cases were
stained for SOX11 by means of the new mouse mono-
clonal anti-SOX11 antibodies anti-SOX11MRQ-58 (Cell
Marque, Rocklin, CA) and anti-SOX11143 (AMAb90502,
clone CL0143; Atlas Antibodies, Stockholm, Sweden),
the latter being raised against the same peptide as is the
mouse monoclonal anti-SOX11142 (AMAb90501, clone
CL0142; Atlas Antibodies).4,6 A goat polyclonal anti-
SOX11sc-17347 (C-20, sc-17347; Santa Cruz Biotechnology
Inc., Santa Cruz, CA), raised against a peptide mapping
near the C-terminus,18 was also used. For comparison
purposes, 59 cases stained with the rabbit polyclonal anti-
SOX11HPA000536 (HPA000536; Atlas Antibodies) in a
previous study4 were also included. Speciﬁc conditions of
use for each antibody are provided in Table 1, Supplemental
Digital Content 1 (http://links.lww.com/PAS/A183).
An interphase ﬂuorescence in situ hybridization
analysis for the t(11;14) translocation using a dual-color
dual-fusion probe (Vysis; Abbott Molecular, Abbot Park,
IL) was performed for all 9 cyclin D1-negative MCL
cases, as previously described.19
Cell Lines and Western Blot Analysis
Protein extract preparations were obtained from the
MCL cell line JVM2, which has been previously shown to
lack SOX11 expression,20 as well as from the nonlymphoid
HEK293 cell line and 2 HEK293 cell lines stably transfected
with vectors encoding human inﬂuenza hemagglutinin (HA)-
tagged SOX4-HA (HEK293-SOX4-HA) and SOX11-HA
proteins (HEK293-SOX11-HA), respectively.20,21 The ex-
pression plasmids pcDNA3-SOX11-HA and pcDNA3-
SOX4-HA were generated as previously described.20 For
Western blot analysis, 50mg total protein extract from
JVM2, 50mg from HEK293, and 5mg from both HEK293-
SOX11-HA and HEK293-SOX4-HA were used. Four dif-
ferent anti-SOX11 antibodies were applied: anti-SOX11143,
anti-SOX11142, anti-SOX11MRQ-58, and anti-SOX11sc-17347.
A mouse monoclonal anti–glyceraldehyde 3-phosphate de-
hydrogenase antibody (A-3; Santa Cruz Biotechnology Inc.)
served as loading control. Membranes were developed with
Pierce ECL Western blot substrate (Thermo Scientific Inc.,
Erembodegem, Belgium) and visualized on a LAS4000 de-
vice (Fujifilm, Du¨sseldorf, Germany). Protein quantification
was done with Image Gauge software (Fujifilm).
SOX11 Expression by Microarray and
Quantitative Reverse Transcriptase Polymerase
Chain Reaction
SOX11 mRNA expression was investigated by quan-
titative reverse transcriptase polymerase chain reaction
(qRT-PCR) in 23 cyclin D1-positive MCL cases and in 2
diﬀuse large B-cell lymphoma (DLBCL) cases, as previously
described.8,20 Brieﬂy, total mRNA was extracted from fro-
zen tissue samples or FFPE tissue blocks, and potential re-
sidual DNA was removed using the TURBO DNA-free kit
(Applied Biosystems, Foster City, CA). The cDNA synthesis
was carried out from 500 to 800ng total mRNA, and the
product was ampliﬁed and quantiﬁed using TaqMan Uni-
versal PCR Master Mix (Applied Biosystems), Taq-
ManMGB Probes, and primers designed using Primer
Express Version 2.0: SOX11 (probe 50-TTTTAACCACG
GATAATTG-30; forward primer 50-CATGTAGACTAA
TGCAGCCATTGG-30; reverse primer 50-CACGGAG
CACGTGTCAATTG-30). The cDNA was analyzed using
duplicates in an ABI Prism 7900HT Fast Sequence De-
tection System (Applied Biosystems). Relative quantiﬁcation
of gene expression was performed with the 2DDCt method
using human b-glucuronidase as the endogenous control
and Universal Human Reference RNA (Stratagene;
Agilent Technologies, Santa Clara, CA) as the mathematical
calibrator.
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RESULTS
Characterization of Monoclonal SOX11
Antibodies in a Western Blot Assay
All monoclonal anti-SOX11 antibodies were initially
tested in a Western blot assay, together with the previously
described polyclonal anti-SOX11sc-17347.18 For this purpose,
protein extracts of the MCL cell line JVM2, which does not
express SOX11, and of the nonlymphoid HEK293, HEK293-
SOX4-HA, and HEK293-SOX11-HA cell lines were used.
Polyclonal anti-SOX11sc-17347 allowed the detection of a
speciﬁc band on the protein extract of the HEK293-SOX11-
HA and no band on the other cell lines. Anti-SOX11143
highlighted a strong band for HEK293-SOX11-HA and a
weak band of the same size in the HEK293-SOX4-HA cell
line corresponding to SOX4, whereas no band was detected
for the nontransfected HEK293 (not shown) and JVM2 cell
lines. Similar results were obtained with anti-SOX11142
(Fig. 1). The anti-SOX11MRQ-58 only highlighted the band
corresponding to SOX11 for HEK293-SOX11-HA. These
data suggest although anti-SOX11142 and anti-SOX11143
antibodies recognized overexpressed SOX4, even though to a
lesser extent, the anti-SOX11sc-17347 and anti-SOX11MRQ-58
did not cross-react with SOX4.
Then, we compared the SOX11/SOX4 signal in-
tensity ratios for anti-SOX11143 and anti-SOX11142,
which were 14.2 and 3.5, respectively, indicating 4.0 times
higher speciﬁcity for anti-SOX11143. Finally, the intensity
ratios for the signals of SOX11, which were normalized
over the loading control glyceraldehyde 3-phosphate de-
hydrogenase, indicated that anti-SOX11143 is more sen-
sitive than anti-SOX11142 and anti-SOX11sc-17347 (signal
intensity ratios for SOX11 anti-SOX11143/anti-SOX11142
was 8.1 and anti-SOX11143/anti-SOX11sc-17347 was 12.4).
IHC Detection of SOX11 Correlates With mRNA
Levels in MCL
The study of the protein detection on FFPE tissue
and the comparison with mRNA levels of SOX11 was
performed by both qRT-PCR and IHC in 23 cyclin D1-
positive MCL. For IHC staining, anti-SOX11143, anti-
SOX11142, anti-SOX11sc-17347, and anti-SOX11MRQ-58
were used.
In positive cases, nuclear staining with at least weak
intensity was detected in most cells, whereas negative
cases presented with complete absent nuclear staining.
Results of the IHC and mRNA levels of SOX11 are
shown in Table 2. Brieﬂy, qRT-PCR values for SOX11
TABLE 1. IHC SOX11 Expression in a Series of Cyclin D1-positive or Cyclin D1-negative Lymphomas, Using the Mouse
Monoclonal anti-SOX11MRQ-58, Anti-SOX11143, and the Goat Polyclonal Anti-SOX11sc-17347 Antibody
CCND1 Diagnosis
Mouse Monoclonal
Anti-SOX11MRQ-58 SOX11
Positive/Total Cases (%)
(n=205)
Mouse Monoclonal
Anti-SOX11143 SOX11
Positive/Total Cases (%)
(n=209)
Goat Polyclonal
Anti-SOX11sc-17347 SOX11
Positive/Total Cases (%)
(n=177)
Negative B-LBL 0/4 2/4 (50) 0/4
T-LBL 0/4 4/4 (100) 1/3 (33)
CLL 0/9 0/9 0/9
HCL 0/3 0/3 1/3 (33)
PCM/Plasmacytoma 0/4 0/4 0/3
MZL 0/10 0/10 0/10
FL 0/8 0/8 0/1
MCL 9/9 (100) 9/9 (100) 9/9 (100)
DLBCL 0/43 2/43 (5) 1/35 (3)
PBL 0/9 0/9 0/7
PEL 0/2 0/2 0/2
BL 0/32 22/32 (69) 6/32 (19)
BCLU 0/5 0/5 1/4 (25)
T-PLL 0/2 1/2 (50) 0/2
Extranodal NK/T-cell
lymphoma
0/1 0/1 0/1
EATL II 0/1 0/1 0/1
HSTL 0/3 0/3 0/3
PTCL, NOS 0/11 0/11 0/10
AITL 0/6 0/6 0/4
ALCL ALK+ 0/3 0/3 0/3
ALCL ALK 0/1 0/1 0/1
NLPHL 0/1 0/1 —
cHL 0/5 0/5 0/1
Positive HCL 0/2 0/2 0/2
PCM/Plasmacytoma 0/4 0/4 0/4
MCL 20/23 (87) 20/27 (74) 18/23 (78)
AITL indicates angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; BCLU, B-cell lymphoma unclassiﬁed with features intermediate between
DLBCL and BL; B-LBL, B-lymphoblastic lymphoma; cHL, classical Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; EATL II, enteropathy-associated T-cell
lymphoma type II; FL, follicular lymphoma; HSTL, hepatosplenic T-cell lymphoma; MZL, marginal zone lymphoma; NLPHL, nodular lymphocyte predominant Hodgkin
lymphoma; PBL, plasmablastic lymphoma; PCM, plasma cell myeloma; PEL, primary eﬀusion lymphoma; PTCL NOS, peripheral T-cell lymphoma not otherwise
speciﬁed; T-LBL, T-lymphoblastic lymphoma; T-PLL, T-cell prolymphocytic leukemia.
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ranged from 0.03 to 90.30. For all 4 antibodies, IHC for
SOX11 resulted negative in cases with qRT-PCR values
r1.21 and positive for values Z9.57. Some discordance
in the immunostaining with the 4 antibodies was instead
observed in 2 cases with intermediate mRNA levels lying
between 1.21 and 9.57 (3.53 and 3.88, respectively)
(Table 2).
Cyclin D1 and SOX11 Protein Expression in MCL
and Other Lymphomas
We analyzed a series of FFPE tissues from diﬀerent
lymphoma subtypes and reactive lymphoid tissues to eval-
uate the possible use of these antibodies in routine diag-
nosis. Included were 9 immunophenotypically and
genetically characterized cases of cyclin D1-negative MCL,
which all lacked cyclin D1 expression by IHC and a t(11;14)
translocation by ﬂuorescence in situ hybridization analysis.
All positive cases exhibited distinct nuclear staining
with monoclonal anti-SOX11143 and anti-SOX11MRQ-58,
and a more heterogenous expression was observed with
polyclonal anti-SOX11sc-17347. Results are summarized
in Table 1.
Brieﬂy, all 9 cyclin D1-negative MCLs were positive
with both monoclonal antibodies. Among cyclin D1-positive
MCL cases, 20/27 (74%) were positive with anti-SOX11143
(Fig. 2) and 20/23 (84%) with anti-SOX11MRQ-58, although
with weaker staining (Table 2). None of the non-MCL cases
was positive using the anti-SOXMRQ-58. Nevertheless,
SOX11 expression was observed in 31/173 (18%) non-MCL
cases using anti-SOX11143 and in 10/145 (7%) non-MCL
cases using anti-SOX11sc-17347. Two DLBCL cases were
positive with anti-SOX11143 (Fig. 3), and one of them was
also positive with anti-SOX11sc-17347, although with weaker
expression levels. None of these 2 cases has SOX11 mRNA
expression by qRT-PCR. Moreover, we observed a weak
nuclear staining in follicular dendritic cells (FDC) and in the
cells of high endothelial venules with the anti-SOX11143,
most evident in angioimmunoblastic T-cell lymphoma.
Among the 59 previously published cases stained
with the polyclonal anti-SOX11HPA000536,4 we identiﬁed 4
discordant cases (7%). All these cases were Burkitt lym-
phoma (BL). Three previously reported negative cases
turned to be positive with anti-SOX11143, and one of
FIGURE 1. Western blot–based evaluation of anti-SOX11 antibodies. Western blot was performed on protein extracts derived
from HEK293-SOX11-HA (A), JVM2 (B), and HEK293-SOX4-HA cell lines (C). Polyclonal anti-SOX11sc-17347 antibody merely
revealed a specific band at 60 to 80 kDa for the HEK293-SOX11-HA cell line. Monoclonal anti-SOX11143 and anti-SOX11142
antibodies highlighted a band of the same size for HEK293-SOX11-HA and a weaker one for HEK293-SOX4-HA, which was not
detected with anti-SOX11MRQ-58. Anti–glyceraldehyde 3-phosphate dehydrogenase antibody was used as a loading control.
TABLE 2. Protein and mRNA Levels of SOX11 Expression by
IHC and qRT-PCR on a Series of Cyclin D1-positive MCL
Case SOX11143 SOX11142 SOX11MRQ58 SOX11sc-17347
qRT-
PCR
1     0.03
2     0.79
3     1.21
4 +  + + 3.53
5  +   3.88
6 + + + + 9.57
7 + + + + 9.97
8 + + + + 13.21
9 + + + + 13.32
10 + + + + 14.87
11 + + + NP 18.36
12 + + + + 19.56
13 + + + + 21.03
14 + + + + 23.80
15 + + + + 24.32
16 + + + + 28.69
17 + + + + 30.33
18 + + + + 30.53
19 + + + + 34.06
20 + + + + 35.61
21 + + + + 36.14
22 + + + + 38.40
23 + + + + 90.30
Cases with qRT-PCR values r1.21 resulted as negative on IHC for SOX11,
whereas cases resulted as SOX11 positive for qRT-PCR values Z9.57. qRT-PCR
was performed in all cases on frozen material.
NP indicates not performed.
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them was also positive with anti-SOX11sc-17347. One pre-
viously reported positive BL did not shown expression
with anti-SOX11sc-17347. None of the discordant cases
showed expression with anti-SOX11MRQ-58.
DISCUSSION
Here, we present the new mouse monoclonal anti-
SOX11 antibodies, which show very good performance
on FFPE tissue samples and are therefore suitable for
routine diagnostic testing. SOX11 represents an im-
portant diagnostic marker in MCL, as the presence of
high levels of SOX11 mRNA and the protein in a nuclear
localization are reported in most MCL cases, independent
of their cyclin D1 status.4,16 However, no study on the
comparison between IHC detection of anti-SOX11 anti-
bodies with SOX11 mRNA levels has been conducted so
far. This might represent an important issue, as post-
transcriptional regulation and posttranslational mod-
iﬁcations can lead to changes in protein levels, and in
routine diagnostic testing SOX11 is usually detected at
the protein level by means of IHC. SOX proteins may be
modiﬁed by ubiquitin and small ubiquitin-like modiﬁer,
which can aﬀect their stability and subcellular local-
ization.22,23 On a series of 23 cyclin D1-positive MCL
cases, we could show that both anti-SOX11143 and anti-
SOX11MRQ-58 can detect SOX11 protein in all cases with
qRT-PCR values >9.57. A similar correlation was obtained
with 2 other antibodies, that is, anti-SOX11HPA000536 and
anti-SOX11142, and minor diﬀerences were merely observed
in 2 cases presenting with almost identical qRT-PCR values
lying close to the IHC detection level. This suggests that
changes in posttranscriptional and posttranslational mod-
iﬁcations have a minor impact on the SOX11 cutoﬀ value for
protein detection on IHC.
The properties of anti-SOX11 antibodies were further
studied on Western blot on extracts of cells overexpressing
SOX11, as well as SOX4, as this represents the protein with
highest homology belonging to the same subgroup, and
were compared with those of anti-SOX11142 and anti-
SOX11sc-17347. Anti-SOX11143 recognized SOX11 and, to a
far lesser extent, SOX4 similarly to anti-SOX11142, which
was raised against the same peptide of SOX11. However,
the speciﬁcity and sensitivity of anti-SOX11143 for SOX11
FIGURE 2. IHC analysis on cyclin D1-positive and cyclin D1-negative MCL. Detection of nuclear SOX11 expression in cyclin D1-
negative (A and C) and in cyclin D1-positive cases (B and D). A and B, SOX11 staining using monoclonal anti-SOX11143. C and D,
cyclin D1 staining.
Soldini et al Am J Surg Pathol  Volume 38, Number 1, January 2014
90 | www.ajsp.com r 2013 Lippincott Williams & Wilkins
were 4.0 and 8.1 times higher, respectively, when compared
with the anti-SOX11142 antibody. Anti-SOX11sc-17347,
which on Western blot assay gives very speciﬁc results, is
12.4 times less sensitive than anti-SOX11143 antibody. The
anti-SOX11MRQ-58 did not showed cross-reactivity with
SOX4.
In our series of 209 primary lymphoid tumors, im-
munostaining with anti-SOX11143 gave results that are
FIGURE 3. IHC results of SOX11 expression in lymphomas other than MCL using monoclonal anti-SOX11143 antibody. Nuclear
SOX11 expression in B-lymphoblastic lymphoma (A), T-lymphoblastic lymphoma (B), BL (C), T-cell prolymphocytic leukemia (D),
DLBCL (E), and anaplastic large cell lymphoma, ALK negative (F).
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mostly consistent with those previously reported
(Table 3).4–7,16 A fraction of the 209 lymphomas pre-
sented herein was included in a previous study that used
polyclonal anti-SOX11HPA000536 and showed highly con-
cordant results.4 Most cases of this same series were ad-
ditionally stained with the polyclonal anti-SOX11sc-17347,
and results were similar, apart from a higher number of
negative cases with anti-SOX11sc-17347, which might be
explained by its lower sensitivity on Western blot. Two of
43 DLBCL cases in our series showed weak nuclear
SOX11 expression, similarly to that reported in a pre-
vious study.5,24 qRT-PCR of these 2 cases was performed,
which resulted in the absence of SOX11 transcript. These
cases were also negative for cyclin D1. The absence of
these 2 markers excludes a pleomorphic variant of MCL.
These data, together with the cross-reactivity of the an-
tibody observed on Western blot assay for SOX4, suggest
that in rare cases weak nuclear positivity might be due to
the high homology of the 2 proteins.25 Analysis of data
derived from previously published gene expression proﬁle
studies showed that some DLBCLs may express SOX4 but
are negative for SOX11.26 The nuclear staining observed in
FDC and endothelial cells of angioimmunoblastic T-cell
lymphoma with monoclonal anti-SOX11143 might also be
due to a cross-reaction with SOX4; however, the same
positivity was observed with the anti-SOX11sc-17347, which
does not recognize SOX4 on Western blot. This suggests
that SOX11 could be expressed in these 2 cell populations.
In this regard, SOX11 expression has been reported in FDC
neoplasms27 as well as in endothelial cells and FDC of
MCL in situ.28 To clarify this issue, additional studies are
needed, which might reveal a potential role of SOX11 as a
marker for these 2 cell populations and for tumors deriving
from them. Importantly, the good performance of the
monoclonal anti-SOX11143 and anti-SOX11MRQ-58 on
FFPE tissue samples is further supported by the fact that
none of the cases of our series presented with unspeciﬁc
cytoplasmic staining, in contrast with previous observations
with polyclonal antibodies.4,5
Some studies have reported SOX11 expression in
cyclin D1-positive hairy cell leukemia (HCL),6,7 which,
together with data on transcription of SOX11 and cyclin
D1 in B-cell lymphomas,29 suggested a possible depend-
ence between SOX11 and cyclin D1 expression. In our
series, however, all 5 HCL cases (3 of them being cyclin
D1 positive and 2 cyclin D1 negative) were negative for
TABLE 3. SOX11 IHC Expression Lymphomas in Previous Studies
n (%)
Diagnosis
SOX11
N-Term
Dictor et al6
SOX11
C-Term
Ek et al5
Monoclonal
SOX11-C1
Nordstro¨m et al17
Polyclonal
Sigma/Atlas
Zeng et al16
Polyclonal Atlas
Mozos et al4
Polyclonal Atlas
Chen et al7
Polyclonal Atlas
Ek et al5
B-LBL 8/9 (89) 3/5 (60) 0/2 4/5* (80) 1/1 (100)
T-LBL 10/10 (100) 4/5 (80) 0/4 5/5 (100)
CLL 0/6 0/14 0/5 0/12 0/50 0/47
HCL 6/12 (50) 2/3 (67) 0/7 5/10 (50)
LPL 0/1 0/5
PCM 0/9 0/1 0/2 0/30
MZL 0/16 0/5 0/20 0/12
FL 0/4 0/15 0/10 0/22 0/22 0/47
MCL CCND1+ 18/23 (78) 15/16 (94) 30/30 (100) 50/54 (93) 54/57 (95) 26/28 (93)
MCL CCND1 5/5 (100) 12/12 (100) 1/1 (100)
DLBCL 0/31 0/75 0/63 0/30 2/30 (7)
BL 7/14 (50) 3/4 (75) 2/4 (50) 1/5 (20) 2/8 (25)
BCLU 0/6
T-PLL 2/3 (67)
T-LGL 0/1
Extranodal
NK/T-cell 0/4 0/3
EATL 0/2
HSTL 0/1 0/3
MF 0/1
PTCL, NOS 0/4 0/15
AITL 0/3 0/5
ALCL ALK+ 0/4 0/3
ALCL ALK 0/3
NLPHL 0/2 0/5
cHL 0/5 1/36 (3)
*These cases included B-LBL and T-LBL without distinction.
AITL indicates angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; BCLU, B-cell lymphoma unclassiﬁed with features intermediate between
DLBCL and BL; B-LBL, B-lymphoblastic lymphoma; cHL, classical Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; EATL, enteropathy-associated T-cell
lymphoma; FL, follicular lymphoma; HSTL, hepatosplenic T-cell lymphoma; LPL, lymphoplasmacytic lymphoma; MF, mycosis fungoide; MZL, marginal zone lym-
phoma; NLPHL, nodular lymphocyte predominant Hodgkin lymphoma; PCM, plasma cell myeloma; PTCL NOS, peripheral T-cell lymphoma not otherwise speciﬁed;
T-LBL, T-lymphoblastic lymphoma; T-LGL, T-cell large granular lymphoma; T-PLL, T-cell prolymphocytic leukemia.
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anti-SOX11143 and anti-SOX11MRQ-58, which is consistent
with both the recently published results obtained with an-
other monoclonal anti-SOX1117 and data on the absence of
SOX11 mRNA transcript in HCL.5 Only 1 HCL case
showed nuclear staining with anti-SOX11sc-17347; however,
this was negative for cyclin D1. Similarly, SOX11 is absent
in cyclin D1-positive plasma cell myelomas, some of which
carry the same t(11;14) translocation as MCL.4,6,7,30 In
contrast, SOX11 is expressed in lymphomas without
t(11;14), such as BL, T-lymphoblastic lymphoma, and B-
lymphoblastic lymphoma.4,6,16,17 These data suggest that
the expressions of cyclin D1 and SOX11 are independent.
Apart from the translocations of theCCND2 gene, few
data are available on the pathogenesis of cyclin D1-negative
MCL.31 In this regard, SOX11 might play a role in the de-
velopment of cyclin D1-negative MCL, as its expression was
shown to be oncogenic promoting tumor growth in a mouse
model and to block plasmacytic cell diﬀerentiation by forced
induction of the direct target gene PAX5.14 This might also
explain the diﬀerent behavior of SOX11-negative MCL, as
these patients present more frequently with non-nodal leu-
kemic disease and an indolent clinical course, even though
contrasting results have been reported.8,9,18,32
In conclusion, our data support that SOX11 ex-
pression by IHC correlates well with its transcription level.
Most importantly, we have assessed the performance of
several SOX11 antibodies on FFPE tissue sections. At
least, 2 monoclonal antibodies, anti-SOX11143 and anti-
SOX11MRQ-58, are useful in recognize MCL in routine
diagnostic tissues. Although anti-SOX11MRQ-58 seems to be
more speciﬁc for SOX11 recognition in Western blot, anti-
SOX11143 may be more sensitive in IHC.
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